Breaking News
Get 50% Off 0
🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% Off CLAIM SALE
Close

Roche Holding AG (0QQ6)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
281.80 -22.00    -7.24%
12/07 - Closed. Currency in CHF ( Disclaimer )
Type:  Equity
Market:  United Kingdom
ISIN:  CH0012032113 
SEDOL:  BKJ8Y02
  • Volume: 1,078
  • Bid/Ask: 275.00 / 0.00
  • Day's Range: 280.00 - 282.00
Roche Holding 281.80 -22.00 -7.24%

0QQ6 Income Statement

 
Featured here, the Income Statement (earnings report) for Roche Holding AG, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
Advanced Income Statement
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Revenue 14912.5 14912.5 15308 15308
Revenue 14468.5 14468.5 14889.5 14889.5
Other Revenue, Total 444 444 418.5 418.5
Cost of Revenue, Total 3989 3989 3809.5 3809.5
Gross Profit 10923.5 10923.5 11498.5 11498.5
Total Operating Expenses 11349 11349 9982 9982
Selling/General/Admin. Expenses, Total 3492.5 3492.5 3250.5 3250.5
Research & Development 3470.5 3470.5 3302 3302
Depreciation / Amortization - - - -
Interest Expense (Income) - Net Operating -211.5 -211.5 -202.5 -202.5
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 608.5 608.5 -177.5 -177.5
Operating Income 3563.5 3563.5 5326 5326
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets 268.5 268.5 18.5 18.5
Other, Net 842.5 842.5 720.5 720.5
Net Income Before Taxes 2452.5 2452.5 4587 4587
Provision for Income Taxes 55 55 805.5 805.5
Net Income After Taxes 2397.5 2397.5 3781.5 3781.5
Minority Interest 3948 3948 3829 3829
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 2180.5 2180.5 3568.5 3568.5
Total Extraordinary Items - - - -
Net Income 2180.5 2180.5 3568.5 3568.5
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 2180.5 2180.5 3568.5 3568.5
Dilution Adjustment -6.38 -6.38 2.76 2.76
Diluted Net Income 2186.88 2186.88 3565.74 3565.74
Diluted Weighted Average Shares 804 804 804 804
Diluted EPS Excluding Extraordinary Items 2.72 2.72 4.44 4.44
DPS - Common Stock Primary Issue - - - -
Diluted Normalized EPS 2.34 2.34 3.68 3.68
* In Millions of CHF (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RO Comments

Write your thoughts about Roche Holding AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Joe Jordan
Joe Jordan May 21, 2024 5:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
Joe Jordan
Joe Jordan May 21, 2024 5:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. The study found that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo.
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Lee John
Lee John Nov 16, 2020 3:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
Jonny Tr
Jonny Tr May 04, 2020 8:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just like Biolidics. they get approval for Covid19 tests kits in USA
Billy Hanafi
Billy Hanafi Jan 25, 2019 10:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i dont know
edgard hajjar
edgard hajjar May 07, 2018 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is the historical price adjusted for stock splits?
Billy Hanafi
Billy Hanafi May 07, 2018 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i dont know
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email